Palvella Therapeutics: signs a material agreement, completes an acquisition or sale of assets and 8 other items
- Form
- 8-K
- Filed
- Period
- Importance
- Major
- Accession
- 0001437749-24-037515
- Document
- 8-K
- Exhibit 4.1
- Warrants or notes
- Exhibit 10.22
- Material contract
- Exhibit 10.23
- Material contract
- Exhibit 10.24
- Material contract
- Exhibit 10.26
- Material contract
- Exhibit 10.27
- Material contract
- Exhibit 10.29
- Material contract
- Exhibit 10.30
- Material contract
- Exhibit 99.1
- Press release
- Signs a material agreement (1.01)
- Completes an acquisition or sale of assets (2.01)
- Sells unregistered shares (3.02)
- Changes shareholder rights (3.03)
- Reports a change in control (5.01)
- Reports an executive or board change (5.02)
- Amends its charter or bylaws (5.03)
- Changes its ethics code (5.05)
- Changes its shell company status (5.06)
- Discloses other events (8.01)
Not explained yet; the original is on EDGAR.
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Esperion Therapeutics ESPR public float $198M, Jun 30, 2025
- Editas Medicine EDIT public float $191M, Jun 30, 2025
- Rezolute RZLT public float $204M, Dec 31, 2025
- Cardiff Oncology CRDF public float $205M, Jun 30, 2025
- Silence Therapeutics SLN public float $206M, Jun 30, 2025